IQWiG

Drug assessment at a glance: A25-162[1]

Remimazolam (intravenous induction and maintenance of general anaesthesia in adult patients)

20 July 2026

[1] This is a courtesy translation of the summary provided as a service by IQWiG. For further information on the subject matter and the result of the assessment, please refer to the dossier assessment for Project A25-162. The G-BA decides on the added benefit.

Research question for the benefit assessment

Population	Adult patients who require intravenous induction and maintenance of general anaesthesia
Intervention	remimazolam
Comparator	Individualized treatment from a choice of ▪ propofol, etomidate and thiopental (for induction of anaesthesia) ▪ propofol, isoflurane, desflurane and sevoflurane (for maintenance of anaesthesia)
Outcomes	At least one patient-relevant outcome

Overview of positive and negative effects

	Size of the effects	Informative value of the effects
Mortality	∅	–
Morbidity	∅	–
Symptoms	∅	–
Health-related quality of life	∅	–
Side effects	∅	–
	∅ No (suitable) data ↔ No advantage or disadvantage ↑ / ↓ Small advantage/disadvantage ↑↑ / ↓↓ Moderate advantage/disadvantage ↑↑↑ / ↓↓↓ Large advantage/disadvantage	– Not applicable ★ Low ★★ Moderate ★★★ High

Overall: No advantage or disadvantage (no suitable data)

Evidence base and noteworthy aspects

- No suitable data were available.
- There are several potentially relevant studies; however, these were not submitted for the benefit assessment.

References

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Remimazolam (Allgemeinanästhesie); Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung [online]. 2026 [Accessed: 15.05.2026]. URL: https://doi.org/10.60584/A25-162.

Gemeinsamer Bundesausschuss. Nutzenbewertungsverfahren zum Wirkstoff Remimazolam (Einleitung und Aufrechterhaltung der allgemeinen Anästhesie) [online]. 2026 [Accessed: 15.05.2026]. URL: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1298/.

English translations for this project are published at https://www.iqwig.de/en/projects/a25-162.html.

Publisher details

Publisher

Institute for Quality and Efficiency in Health Care (IQWiG)

Address

Siegburger Str. 237
50679 Köln
Germany

Phone: +49 221 35685-0
Fax: +49 221 35685-1
Email: info@iqwig.de
Internet: www.iqwig.de